Obstetrics & Gynecology Track the topics, authors and articles important to you
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Obstetrics & Gynecology 2007;110:601-607
© 2007 by The American College of Obstetricians and Gynecologists
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cahill, A. G.
Right arrow Articles by Stamilio, D. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cahill, A. G.
Right arrow Articles by Stamilio, D. M.
Related Collections
Right arrow Decision analysis
Right arrow General obstetrics
Right arrow Hypertension and PIH

ORIGINAL RESEARCH

Magnesium for Seizure Prophylaxis in Patients With Mild Preeclampsia

Alison G. Cahill, MD1, George A. Macones, MD, MSCE1, Anthony O. Odibo, MD, MSCE1 and David M. Stamilio, MD, MSCE1

From the 1Department of Obstetrics and Gynecology, Washington University in St. Louis, St. Louis, Missouri.

OBJECTIVE: To estimate whether magnesium therapy is the optimal management for women with mild preeclampsia.

METHODS: A decision analytic model was designed for women with mild preeclampsia to estimate whether empiric magnesium therapy or no magnesium therapy is the optimal management strategy. The model considered relevant clinical events: seizure, placental abruption, and magnesium toxicity. Modeled outcomes were maternal mortality, neonatal mortality, and neurologic neonatal compromise. The two strategies were compared based on the probability of clinical events and outcomes and the utilities or values assigned to the outcomes by prior research. Probabilities and utilities were derived from the literature.

RESULTS: The base-case analysis showed that although the no-magnesium strategy results in a 15% reduction in neonatal mortality and avoids most maternal drug toxicity, it produces a twofold increase in maternal death and more neurologically compromised neonates compared with empiric magnesium. The two strategies are essentially equivalent with regard to aggregate maternal and neonatal outcomes (0.9792 compared with 0.9781 utilities). Multivariable sensitivity analysis using Monte Carlo simulation confirmed the decision to be a "toss-up," yielding a similar mean utility for no-magnesium and magnesium strategies (0.9789±0.1374 compared with 0.9784±0.1390, respectively).

CONCLUSION: Our decision model indicates that either strategy, using or not using empiric magnesium sulfate therapy, is acceptable. The clinical decision of whether to use magnesium in patients with mild preeclampsia for seizure prophylaxis should be determined by the physician or institution, considering patient values or preferences and the unique risk-benefit trade-off of each strategy.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by the American College of Obstetricians and Gynecologists.